Cancer Treatment Start-up BeiGene Opens Manufacturing Plant In Suzhou



With two major international industry endorsements already in the bag, after just five years in existence, firm says while remaining committed to having China as its core manufacturing base it is also open to building facilities overseas

BeiGene, the Beijing-based biopharmaceutical start-up, has completed the building of its first own manufacturing plant in the city – a key step in the Nasdaq-listed company’s transformation from clinical-stage developer to commercial maker of cancer medicines.

The new facility in Suzhou Industrial Park, in Jiangsu province, cost 200 million yuan (US$30.2 million) which will help the company to feature capabilities in the whole value chain – discovery, development, industrialised production and sales – of molecularly targeted and immuno-oncology drugs for cancer treatment. It has taken two years to build.



Editorial Team

Our Editorial Team curates "news you can use" from hundreds of local newspapers, magazines, blogs and online sources, press releases, radio and TV news shows from around the world. We take great pride in being providing Daily Business Intelligence that's all business and no politics.